Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 41: 799-804, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Denton, T. A.
Right arrow Articles by Diamond, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Denton, T. A.
Right arrow Articles by Diamond, G. A.

Clinical Chemistry, Vol 41, 799-804, Copyright © 1995 by American Association for Clinical Chemistry

For goodness' sake: expected therapeutic benefit as a basis for healthcare delivery

TA Denton and GA Diamond
Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

The current debate on our healthcare system has focused primarily on the cost of care. Because of drastically rising costs and their burden on our economy, government and the private sector have developed many approaches to reduce these costs. Managed care, special contracting arrangements, and government fiat have all been used to stem the tide of rising costs--with variable success. We propose that the primary goal of healthcare is the provision of patient benefit, and we describe a model that calculates an expected benefit in terms of survival and quality of life. We have applied this model to a cohort of patients undergoing coronary angiography to determine the distributions of benefit. Furthermore, we describe a reimbursement strategy that relates the expected therapeutic benefit to the reimbursement received for that therapy--the greater the benefit, the greater the reimbursement. The future of our healthcare system lies in keeping the patient at the center of the debate on the delicate balance between optimal care and societal cost.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.